Research work in the IBD outpatient clinic

• Phase 2

M20-371 - ABV154 -  Recruitment is ongoing

.

• Phase 3 und 3b

RPC01-3202 - Ozanimod - Induction - Recruitment is ongoing

.

RPC01-3203 - Ozanimod - Maintenance 

.

RPC01-3204 - Ozanimod - OLE

.

GS-US-419-3895 - Filgotinib - Induction and Maintenance - Recruitment is ongoing

.

GS-US-419-3896 - Filgotinib - LTE

.

CNTO1959CRD3001 - Guselkumab 

.

M16-000 - Risankizumab - Maintenance and OLE 

.

16T-MC-AMAM - Mirikizumab 

.

I6T-MC-AMAX - Mirikizumab - LTE

• Phase 2 und 2b:

ABX464-104 - ABX464 - OLE

.

CNTO1959UCO3001 - Guselkumab

.

• Phase 3

GS-US-418-3899 - Filgotinib - LTE

.

I6T-MC-AMAP - Mirikizumab - OLE

.

CNTO1959UCO3001 - Guselkumab 

A multicenter, randomized study to evaluate the clinical use of novel molecular markers in the therapy of patients with inflammatory bowel disease (IBD). At the Clinic for Internal Medicine I (Kiel), a research project on molecular medicine in the therapy of chronic inflammatory bowel diseases (IBD) such as Crohn's disease and ulcerative colitis is being carried out. This is done in cooperation with the University Hospital Hamburg-Eppendorf, the Hannover Medical School, the Institute for Clinical Molecular Biology (IKMB), the Institute for Medical Informatics and Statistics (IMIS) and the Dr. Margerete Fischer-Bosch Institute for Clinical Pharmacology (Stuttgart). Novel biomarkers could help to control the drug treatment of patients with chronic inflammatory diseases more precisely and thus achieve more sustainable therapeutic success. In GUIDE-IBD, a project funded by the Federal Ministry of Education and Research (BMBF), we would like to include exactly these biomarkers for the first time in the context of biological therapy for IBD by analyzing your therapy with infliximab. The aim is to investigate whether the use of additional knowledge about the course of the disease through innovative biomarkers can help physicians to make better therapy decisions.

The CARMEN study – your experiences matter!

How does the menstrual cycle affect life with Crohn’s disease or ulcerative colitis? We would like to explore this question in the CARMEN study, whilst also taking psychological and social factors into account.

We are looking for women aged between 18 and 40 with Crohn’s disease or ulcerative colitis who have a regular menstrual cycle, are not currently using hormonal contraception and are not pregnant.

The study will last for three menstrual cycles. During this time, you will complete short online questionnaires daily, wear a fitness tracker, carry out ovulation tests at specific times, and provide hormone samples and weekly stool samples.

By taking part, you will help us to better understand IBD in women and, in the long term, enable more personalised, potentially cycle-based treatment. As compensation for your time and effort, you will receive €100 at the end of the study.

Study leader: Dr Miriam Wiestler

CEDNutriNavigator – The digital guide to a personalised and healthy diet for IBD

People with Crohn’s disease or ulcerative colitis experience their condition in very different ways. There are also many questions when it comes to diet: What is good for me? What can I eat when I have certain symptoms? And which foods might I be intolerant to?

Through our study, we aim to help develop a digital nutrition support tool for IBD: the CEDNutriNavigator.

In future, the CEDNutriNavigator is designed to provide clear and personalised dietary advice. It takes into account, amongst other things, the personal circumstances, symptoms and intolerances that users specify. The recommendations are based on the latest scientific evidence and guidelines.

By taking part, you can help to further develop the IBDNutriNavigator and thus create a digital support tool tailored to the needs of people with Crohn’s disease and ulcerative colitis.

We are conducting the study in collaboration with the Peter L. Reichertz Institute for Medical Informatics.

Study leaders: Dr Miriam Wiestler (MHH) and Dr Mattea Müller (PLRI)